Twist Bioscience Reports Fiscal Q2 2026; Focus Remains on Margin and Cash Flow Sustainability

What happened

Twist Bioscience announced its fiscal second quarter 2026 results, though the press release provides limited specific financial detail. The report comes after the prior quarter's encouraging inflection, where gross margin reached 53.4% and free cash flow turned positive, aided by the Wilsonville consolidation and Atlas data storage divestiture. However, management has yet to demonstrate sustained profitability, and competitive intensity from scaled oligo suppliers like IDT and GenScript, along with research-spend cyclicality, continue to pressure pricing and market share. Investors will need to see the full earnings release to assess whether gross margin remained above 50% and cash flow stayed positive—key watch items from the DeepValue report. Until these metrics are confirmed, the HOLD thesis remains intact, as the durability of recent operational improvements is unproven.

Implication

If Twist sustains >50% gross margin and positive FCF for multiple quarters, the thesis could shift to BUY, reflecting successful Wilsonville leverage and NGS share gains. Conversely, a reversion to low-40s margins and negative cash flow would warrant downgrade to SELL.

Thesis delta

The fiscal Q2 announcement does not materially alter the thesis; it is a checkpoint on margin and cash flow sustainability. No upgrade or downgrade catalyst yet—watch for the full filing to confirm whether the Q3 FY2025 inflection is becoming a trend.